Abstract
No public abstract is available from the verified source records.
Claus F Vogelmeier, David M G Halpin, Alvar Agusti, Shawn Aaron, Bartolome R Celli, David Halpin, Maria Montes De Oca, Obianuju B Ozoh, Alberto Papi, Ian Pavord, Nicolas Roche, Sundeep Salvi, Thierry Troosters, Jadwiga A Wedzicha, Jinping Zheng
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
2026
Is disease stability an attainable chronic obstructive pulmonary disease treatment goal?
10.1164/rccm.202406-1254ci · 2025
Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review
10.1186/s12931-022-02123-53 · 2022
Susceptibility to exacerbation in chronic obstructive pulmonary disease
10.1056/nejmoa0909883 · 2010
Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations
10.1183/13993003.02240-2023 · 2024
Risk of death and cardiovascular events following an exacerbation of COPD: the EXACOS-CV US study
10.2147/copd.s438893 · 2024
The sustained increase of cardiovascular risk following COPD exacerbations: meta-analyses of the EXACOS-CV studies
10.1183/23120541.01091-2024 · 2025
An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal
10.1164/rccm.202108-1819pp · 2021
Association between Rome classification among hospitalized patients with COPD exacerbations and short-term and intermediate-term outcomes
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.chest.2023.07.021 · 2023
Validation study of Rome criteria for assessing COPD exacerbation severity and predicting clinical outcomes: Turkish Thoracic Society COPD Assembly
10.2147/copd.s554744 · 2025
Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) model
10.1016/s2213-2600(25)00362-5 · 2026
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: an analysis of the PRIMUS study
10.18553/jmcp.2022.28.12.1366 · 2022
Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
10.1186/s12931-023-02523-1 · 2023
Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts
10.1056/nejmoa2303951 · 2023
Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation
10.1056/nejmoa2401304 · 2024
Mepolizumab for eosinophilic chronic obstructive pulmonary disease
10.1056/nejmoa1708208 · 2017
Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype
10.1056/nejmoa2413181 · 2025
No additional external references are available.